All News
New ACR/EULAR Guideline Expands RA Remission Definition
Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
Read ArticleIncreasing Prevalence of RA, PsA and AS in the UK
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.
Read ArticlePrevotella Immune Response in Both Pre-Clinical & Established RA
In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc).
Read ArticleMiners Face Increased Risk of Rheumatoid Arthritis
Add "hard rock" mining to the list of occupations associated with high rates of rheumatoid arthritis (RA), a new study indicated, with silica exposure the presumed malefactor.
Read ArticleSecond Efforts in Treating RA Partial Responders
The results of a treat-to-target (T2T) combination therapy trial in patients with early rheumatoid arthritis (RA) show that if patients fail to respond initially, then a second, more intensified regimen can turn initial nonresponders into responders.
Read ArticleGood Outcomes with TNF Blocker Use During RA Pregnancies
A prospective cohort study of treatment and pregnancy outcomes in women with RA shows that TNF inhibitor use during pregnancy did not increase the risk of adverse pregnancy outcomes, but instead led to more positive outcomes such as fewer low-birth-weight deliveries.
Read ArticleNo Special Heart Risk With JAK Inhibitors, Study Finds
Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:


